What does this source bring?
In LAMP, atropine 0,05% provided greater control of refraction and axis extension than 0,025% and 0,01% in the first year of the study.
The response was concentration dependent; this result does not establish the optimal dose for each child.
CLAIM-LAMPScope of testing and verification
- The role of the record
- Source of the claim
- Population
- Children 4–12 years old, Hong Kong
- N
- 438
- Geography
- Hong Kong
- Observation (months)
- 12
- Comparator
- 0,05%, 0,025%, 0,01% and placebo
- Result
- In LAMP, atropine 0,05% provided greater control of refraction and axis extension than 0,025% and 0,01% in the first year of the study.
- Safety
- Pupil, accommodation, acuity and quality of life were monitored.
- Device/structure
- Not applicable / not determined within the verified range
- Publisher of the publication
- Elsevier BV
- Financing
- Not determined within the proven range; see the declaration in full text.
- Conflicts of interest
- Not determined within the proven range. The absence of confirmation does not mean the absence of conflict.
- DOI
- 10.1016/j.ophtha.2018.05.029
- PMID
- 30514630
- What was checked
- Bibliographic metadata and abstract in Europe PMC / PubMed; Crossref metadata
- Date of verification
- 2026-09-09
This is the editorial card of the publication. The description does not replace the full text, supplementary data or instructions for a specific device.